LAS VEGAS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- via IBN -- Due to a website maintenance error, a draft of a letter to BioAdaptives^? (OTC: BDPT) shareholders was made available on the BioAdaptives^? website. While the timing was unfortunate, it raised awareness of an upcoming event critical for the long-term health of BioAdaptives^?.

On Jan. 1, 2020, BioAdaptives^? had 18,576,379 shares of common stock issued and outstanding. Then, stock was traded for funding to raise money to develop business plans, with the money spent on those plans. Unfortunately, the plans did not work, and the process was repeated until the quarterly report ending June 30, 2024, showed 1,231,728,974 common shares issued and outstanding without increasing revenue. That is roughly a 6,530% increase in shares in less than five years without success in the business plan. For BioAdaptives Inc. to reach just $1.00 per share, the market would have to view BioAdaptives as a $1,213,728,974 company. That number of shares guarantees the stock will remain in the sub-penny range.

Why is BioAdaptives^? planning a reverse stock split?
        
When the new management took over, it was mutually agreed with past management that a new direction and a reverse split were needed. There was no sense in completing a reverse split until an achievable plan was in place that allowed the company to grow and have substance. Over the next few weeks and months, several outstanding products will be brought to market, and we expect BioAdaptives^? to soon see increased revenue followed by profitability. The new CEO, James Keener, has a history of turning around underperforming companies. He stopped everything and changed direction to turn BioAdaptives^? around. He moved because he is committed to making BioAdaptives^? a genuine company with meaningful revenue, profits and share price.

The new product line has solid science behind it and high efficacy. We will soon be producing new offerings as we fill out our lines of human and animal products.

The marketing plan for our new products is much more comprehensive, with new distribution channels and standout packaging. This reverse is just one crucial step to turning around an underperforming company.

About BioAdaptives

BioAdaptives, Inc. develops and distributes natural herbal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; stress resistance; endurance; recovery from injury, illness, and exercise; and anti-aging properties. Our current dietary supplement formulations are carefully selected from the best sources worldwide, and proprietary methods are utilized to enhance the bioavailability of nutrients. Our products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, pain relief and improved appearance.